Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.
Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L.
Weber J, et al. Among authors: taylor am.
Oncologist. 2024 Nov 19:oyae289. doi: 10.1093/oncolo/oyae289. Online ahead of print.
Oncologist. 2024.
PMID: 39560953